The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
about
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell linesCancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer MedicinePredictive biomarkers in precision medicine and drug development against lung cancerUsing CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60In vitro human cell line models to predict clinical response to anticancer drugsUsing drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancerChoosing the right cell line for renal cell cancer researchUsing Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyThe impact of the Cancer Genome Atlas on lung cancer.Topoisomerase I alone is sufficient to produce short DNA deletions and can also reverse nicks at ribonucleotide sitesA framework for application of metabolic modeling in yeast to predict the effects of nsSNV in human orthologsNCI-60 whole exome sequencing and pharmacological CellMiner analysesHigh resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMinerSystematic Quality Control Analysis of LINCS DatamiR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cellsCancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerNCI-60 Cell Line Screening: A Radical Departure in its Time.Impact of germline and somatic missense variations on drug binding sitesThe NCI-60 Methylome and Its Integration into CellMiner.Non-synonymous variations in cancer and their effects on the human proteome: workflow for NGS data biocuration and proteome-wide analysis of TCGA data.Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cellsCellMiner Companion: an interactive web application to explore CellMiner NCI-60 data.A phase i study of DMS612, a novel bifunctional alkylating agent.A multivariate approach to the integration of multi-omics datasetsDetecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines.Patient-derived xenograft models: an emerging platform for translational cancer researchBioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerHuman germline and pan-cancer variomes and their distinct functional profilesRADIA: RNA and DNA integrated analysis for somatic mutation detection.The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapiesA mathematical model for short-term vs. long-term survival in patients with glioma.Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma.Target enrichment using parallel nanoliter quantitative PCR amplification.CMPD: cancer mutant proteome database.Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.Colon cancer-associated mutator DNA polymerase δ variant causes expansion of dNTP pools increasing its own infidelityPools and Pols: Mechanism of a mutator phenotype.Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.
P2860
Q16880225-501DD5D5-55EA-40BD-826E-EABC695C6F3CQ17577870-E05BF3EF-B56A-4D4E-9721-B719BF92D889Q1881253-2DBD4BCD-F2AD-4ED5-8B16-CEC9598082C6Q28334584-69BA6BC7-9540-4A91-B40C-A7969F8BC65AQ28334700-F7162BFF-FA3A-4C49-AB26-9B2843FB99CCQ28519412-12916C73-3846-45C0-A376-60C5A9F229DCQ4649475-C0DCF7C4-2E77-40CE-93E1-BBB362C0D24EQ50432263-AF801948-4FB8-44B0-9339-7876DB87B140Q50952937-D8932DA6-072F-4842-A051-3D17DB26E719Q51838638-7F640F37-8253-44A9-8906-F91EF16E0575Q5206280-CD0372D2-0F50-4352-B2A7-E16BF703B6A6Q54604950-EB9B28B3-5F8E-4E04-B7AD-F9186DE12855Q54606041-9713BAD1-4446-4674-97D9-0C1A6BBFDA5EQ54608371-59B97522-3A77-4DE1-A9A1-71695816C177Q54798471-BBF7BD6E-246C-4E4C-850E-C5F9A845AC5EQ54808374-A3C438E8-B2B9-400C-8961-7C017C4C621BQ54809015-41FB0DC2-A6B0-4660-B9C8-E6DED41C917FQ54814074-900906F7-C918-4AAB-AD8A-4A7DDD6D6904Q54832197-503040D4-AF35-479C-9B02-788683F528A3Q54881683-16F44D6E-DCBD-4B86-B9CD-020E6795C6B9Q54882006-2AEB02D5-0289-4D8B-8AD5-5591E5C5DE4CQ54889812-CDD01917-BFCF-43B8-A65D-7397FABCAB00Q54890155-DF387911-7F7F-4D30-9224-D66C38DAA1ADQ54890156-19310083-F0A8-4AAB-AA29-D85C915D5030Q54895774-7982D513-3514-4F70-B710-F22803BDA589Q54897382-16AD94D8-93BD-45CA-9761-6A1A2CEAE0B0Q54900052-63CE5DF2-E119-46A8-87DC-A869E5733B0AQ54902908-1DD5F9A8-C763-4632-8865-DC83BC0F405EQ54903981-40013444-2D69-4E64-8381-A68A578DA4F5Q54906365-9F63DB5A-43D8-44BC-A20A-354DB31B08C1Q54907948-C0AAA39E-4A96-4ACF-A873-5705DE879448Q54907958-3E030CBA-CE75-4FB4-B664-B3CDC8351562Q54908034-5E9CF326-3471-46A5-B992-8D008E605ECBQ54908057-80A5D8EC-94A9-4586-A592-504C1163E083Q54908074-30FA8F13-DF5E-4E8B-8A6C-FF59834E9C2AQ54937005-CA73B399-68A5-4D22-9595-17C35D869001Q54937010-E9E36359-3376-413C-A7FB-367C0A764BE8Q54937011-968545E2-A056-4CEA-8221-9CD84C1422E9Q54937014-3167E1FE-21B0-447B-8089-BBD28FD15AB7Q54951245-7FCF61BC-54C8-4A14-8245-5C8AB5E92D00
P1343
Q23058134-FB1ED26E-100E-4C8D-A6C0-5EB3D119BDD8Q26800337-F4900F35-06A2-44B1-8A6C-1291DBA02804Q26824536-C8121E5B-DF3C-4D5D-90C2-5E349B7E04C6Q26826831-8D72454E-A4D0-4B5C-A869-C31FF7CB355EQ27000665-B321095F-12CF-4410-B85E-58B8B2B6843AQ27320602-FBD34F62-8B61-454C-AAFE-1DB056F1E895Q28073283-1DD37AD6-B361-4E88-BE85-FC8EC7D1C1D9Q28076097-66363AA0-D1A5-4DC0-B193-EDF635562E64Q28084190-01BAB09C-0561-49EE-8F12-5475A8F0EFF9Q28260713-7EF2D01F-3D54-429D-BE43-EDEF1A9EF3A1Q28539707-8908C0CB-61B7-44D1-8DDD-319B630C6F33Q28540834-4B242E04-747E-4056-A814-C0D02D6307EDQ28541555-EB8EC2EA-6503-4E00-B104-AF6371DC5D84Q28818488-776691A8-3D8C-44D6-8655-215EAB1F1779Q28829677-2E11DA6B-67F9-4A1B-BF28-5A6DDA0FF6C1Q29615679-D6444B75-0C2D-4995-BAC5-FA48A188FABAQ30383428-DAD57CE5-AEA9-4BCC-B52B-9AF56F987DE5Q30383865-A2DC62DE-8979-4126-84B1-9E5C08B5B063Q30490461-2730E81A-C7B6-40C6-9F86-DBCEC628AF17Q30742924-B59FF9A8-01E4-40D7-88A9-0D22077534BFQ30860570-0906621E-6F31-44DA-B21A-B467A65305DBQ31012806-EEC8BFFA-1819-43B2-9469-AF0876A512DBQ31092227-773363D4-06CE-4872-802C-4B2251C9D914Q33419113-81C093E6-A7AB-4F3C-BBBA-315A6315D595Q33739977-158D238E-53AE-4761-B486-16692CDD1309Q33913055-702210A9-6BA9-4C2C-A1EF-8FFF9779B35CQ34205518-0A962FAF-DD64-49CD-9179-B4003784049EQ34295621-609AFE21-F892-4351-99E9-06EBCFE00520Q34312953-82AABE02-1DC1-4716-97C9-6803C63B3813Q34535183-E8ACF5CF-B699-4589-A737-10733C6AD712Q34619156-BB71A14E-9F12-4ACB-8E20-5DDF18B9044FQ34704964-90468F33-8BBC-4718-9F68-3B2440B85B71Q34729370-FFBB3FD3-FBCC-4223-86B8-DCF37D472C0CQ34983791-74EEBA03-3878-4F82-B712-A5A5DF9CC5F6Q35115643-CFF6F0E5-41A5-407C-BC05-36B4AE524A14Q35254275-DD107294-CB4A-4AB3-98B6-40D199E780D1Q35268479-F5B41573-E983-4A22-8891-41E925A654B7Q35616094-4C89B342-1870-43B1-B69D-0660F8895FFDQ35616334-C6B43873-6A6E-4654-A08D-655D8BFCDD3CQ35632206-94D6247E-D72C-4575-B9AC-2D8B7EBFBFA9
P2860
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The exomes of the NCI-60 panel ...... logy and systems pharmacology.
@en
type
label
The exomes of the NCI-60 panel ...... logy and systems pharmacology.
@en
prefLabel
The exomes of the NCI-60 panel ...... logy and systems pharmacology.
@en
P2093
P2860
P4510
P50
P1433
P1476
The exomes of the NCI-60 panel ...... logy and systems pharmacology.
@en
P2093
Eric C Polley
James H Doroshow
Marbin Pineda
Ogan D Abaan
Paul S Meltzer
Richard M Simon
Robert L Walker
Susan L Holbeck
Sven Bilke
Yevgeniy Gindin
P2860
P304
P356
10.1158/0008-5472.CAN-12-3342
P407
P577
2013-07-15T00:00:00Z